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Osteoarthritis (OA) is a leading cause of disability and source of societal cost in older adults. It is
a whole-joint disease in which all components of the joint are affected involving structural alterations
in the articular cartilage with additional abnormalities especially in subchondral bone, ligaments,
capsule, synovium, and the joint. During the evolution of OA pathology, the compositions, functional
properties, and structures of these tissues undergo marked alterations [1–3]
Patients with OA experience pain as the most disabling symptom. A large proportion of those
patients experience pain sensitization by means of nociceptive, inflammatory, and neuropathic pain
mechanisms arising from structural changes in the joint innervation or from nerve changes in the
peripheral nervous system or spinal cord [4].
The development of targeted therapies against the osteoarthritic processes in cartilage, synovium
or bone will, therefore, require an understanding of the disease status of these joint tissues at the
time of the intervention. Importantly, these interventions will not be successful unless they are
applied at the early stages of the disease before considerable structural and functional alterations
occur in the osteochondral unit [5]. A number of stratifications have been proposed on the basis of
specific pathological processes to classify different mechanistic subgroups, which include an increased
inflammatory component, mechanical overload, metabolic alterations, and cell senescence [6,7].
The purpose of the Special Issue “Osteoarthritis and Cartilage Regeneration: Focus on
Pathophysiology and Molecular Mechanisms” (https://www.mdpi.com/journal/ijms/special_issues/
Osteoarthritis_Cartilage_Regeneration) is to illustrate some recent developments in the field of
pathophysiological mechanisms of osteoarthritis. These include therapeutic pharmacological and
cell-based strategies, as well as biomechanical and biochemical mechanisms in OA pathophysiology,
structure to function relationship of the extracellular matrix, molecular and neuronal pathways in OA,
biomarkers for OA progression, and metabolism.
1. OA and Biomarkers
The development of simple and reliable non-invasive biomarkers of OA, especially the
identification of novel biomarkers that are able to accurately and relatively quickly assess the efficacy
of therapies, is an important goal in clinical rheumatology and orthopedic surgery. It will facilitate the
design and evaluation of clinical trials on DMOADs. There are several biomarkers available in the field
of OA, which assess cartilage degradation in the serum or urine of patients; however, there are very few
that detect the novel formation of cartilage. Therefore, an unmet need in DMOAD development exists,
where non-invasive biomarkers of cartilage formation can provide an early indication of drug efficacy.
In addition, it is known that OA is a disease of the whole joint, with an inflammatory component
that leads to the deterioration and loss of joint function as the disease progresses [8]. Thus, local
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inflammation within OA joint tissues reflected in serum biomarkers led to the understanding that
there is evidence for systemic low-grade inflammation in subsets of OA patients. Bournazou and
colleagues investigated the expression of vascular adhesion protein-1 (VAP-1) in joint tissues and
serum in symptomatic knee osteoarthritis (SKOA) patients and examine whether VAP-1 levels predict
increased risk of disease severity in a cross-sectional study [9]. They observed elevated levels of
soluble (s)VAP-1 in OA synovial fluid and VAP-1 expression in synovium. However, serum sVAP-1
levels in OA patients were lower than in controls and inversely correlated with pain and inflammation
markers (hsCRP and soluble RAGE). Soluble VAP-1 levels in serum were also lower in radiographically
advanced (KL3/4) compared with early KL1/2 knee SKOA patients. With respect to synovial fluid
analyses, it is of interest that local sVAP-1 levels were higher in OA patients than in healthy controls.
However, higher serum sVAP-1 levels in early knee OA patients could be a surrogate marker for less
severe radiographic OA. Their data indicate that VAP-1 and its soluble form, sVAP-1, are potential
markers of OA expressed at early stages of the disease that correlate with age, gender, and OA-related
pain and inflammation.
N-terminal propeptide of type II collagen (PIINP) is a biomarker reflecting cartilage formation and
exists in two main splice variants termed as type IIA and type IIB collagen NH2-propeptide (PIIANP,
PIIBNP). Luo and colleagues aimed to develop an immunoassay assessing these type II collagen
synthesis markers in human blood samples [10]. For that they used a well-characterized antibody
against human PIIBNP to develop a high sensitivity electro-chemiluminescence immunoassay which
recognizes PIIBNP. Serum samples from a cross-sectional knee OA cohort, as well as pediatric and
rheumatoid arthritis samples, were assayed for PIIBNP and PIIANP. They did not observe a significant
correlation between PIIBNP and PIIANP levels when measured PIIBNP in knee OA, rheumatoid
arthritis, and pediatric serum samples. Serum PIIBNP was significantly higher in controls (KL0/1)
compared to OA groups (KL2/3/4). Overall, the authors suggest, that it is unlikely that any single
biomarker can offer sufficient sensitivity and specificity to detect early stages of OA, monitor the
progress of destruction, accurately and quickly assess the efficacy of therapy, and predict the progression
of OA. Thus, there is a need for different types of biochemical markers for different usages in OA.
The authors of this study believe that PIIBNP would be a promising complementary biomarker to the
existing formation marker portfolios.
2. OA and Neuronal Pathways
The importance of the nociceptive nervous system for maintaining tissue homeostasis has been
known for some time, and it also has been suggested that organogenesis and tissue repair are under
neuronal control. Changes in peripheral joint innervation are supposed to be partly responsible for
degenerative alterations in joint tissues, which contribute to development of OA. Various resident cell
types of the musculoskeletal system express receptors for sensory and sympathetic neurotransmitters,
allowing response to peripheral neuronal stimuli. They seem to play a role in pathogenesis of a
priori degenerative joint disorders such as OA. Altogether it is evident that sensory and sympathetic
neurotransmitters have crucial trophic effects which are critical for joint tissue and bone homeostasis [11].
Speichert and colleagues analyzed the contribution of the sympathetic neurotransmitter norepinephrine
(NE) to human articular OA chondrocyte dedifferentiation under physioxic conditions [12]. NE alone
did not affect morphology but, in combination with IL-1ß, markedly accelerated this shift. Moderate
glycosaminoglycan (GAG) staining was observed in untreated and NE-treated cells, while IL-1 strongly
decreased GAG deposition. IL-1β alone or in combination with NE decreased SOX9, type II collagen,
COMP, and aggrecan, and induced MMP13 and ADAMTS4 gene expression, indicating an accelerated
dedifferentiation. This study demonstrated that low-dose IL-1ß is a strong inducer of chondrocyte
dedifferentiation even in short-term culture and under physioxic conditions. Unexpectedly, NE did
not exhibit any effect on monolayer chondrocytes, in either low or in high concentrations, even though
relevant receptors were present. NE was also not able to modulate the effects of low-dose IL-1ß. Thus,
the very low inflammatory status obviously exerts a dominant effect, which massively contributes to
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the chondrocyte dedifferentiation process during OA pathogenesis and should therefore be targeted
early and primarily in OA therapy.
Muschter et al. investigated if the sensory neuropeptide substance P (SP) and the neurokinin
receptor 1 (NK1R) are involved in macrophage mechano-transduction, similar to chondrocytes,
and if alpha-calcitonin gene-related peptide (αCGRP) and the CGRP receptor (CRLR/Ramp1) show
comparable activity [13]. Loading induced NK1R and CRLR/Ramp1 gene expression and altered
protein expression in RAW264.7 macrophages. SP protein and mRNA level decreased after loading
whereas αCGRP mRNA expression was stabilized. SP reduced adhesion in loaded RAW264.7
macrophages and both neuropeptides initially increased the ROS activity followed by a time-dependent
suppression. OA induction sensitized primary bone marrow macrophages (BMM) to caspase 3/7
mediated apoptosis after loading. Loading altered the reactivity to SP and αCGRP regarding adhesion
and ROS production suggesting mechano-dependent alterations in G-protein receptor signaling that
might affect macrophage migration and activity. Furthermore, OA induction altered BMM apoptosis
in response to loading indicating that OA-associated biomechanical alterations also affect the bone
resident macrophage population.
Sluzalska and colleagues investigated the individual effects, which dexamethasone, as well
as agonists of adrenergic and muscarinic receptors, have on phospholipid (PL) classes and species
synthesized and released by human fibroblast-like synoviocytes (FLS) providing further insights
into the regulatory mechanisms controlling PL metabolism in articular joints [14]. Dexamethasone
significantly decreased the biosynthesis of phosphatidylcholine, phosphatidylethanolamine (PE),
PE-based plasmalogen, and sphingomyelin. The addition of RU 486 abolished these effects. A release
of PLs from FLS into nutrient media was not recognized by any of the tested agents. Analysis of
receptor agonists of the sympathetic and parasympathetic nervous system was included to see whether
they can affect PL biosynthesis in FLS. The data reveal that the adrenergic receptor agonists terbutaline
and epinephrine, as well as the muscarinic receptor agonists carbachol and pilocarpine, exert no or only
weak effects on PL synthesis. Dexamethasone is an inhibitor of PL biosynthesis in FLS from human OA
knees but has no impact on PL release from human FLS. Nevertheless, their data support the therapeutic
use of dexamethasone for balancing altered PL compositions during diseases such as OA. Moreover,
adrenergic and cholinergic agonists have only minor influences on phosphatidylethanolamine and
sphingomyelin synthesis and do not modulate their release.
Pituitary adenylate cyclase activating polypeptide (PACAP) is an endogenous neuropeptide also
secreted by non-neural cells, including chondrocytes and it is known that PACAP signaling is involved
in the regulation of chondrogenesis. Szentleleky and colleagues demonstrated that exogenous PACAP
lowered hyaluronidase and aggrecanase expression and activity during cellular stress in primary
chicken micromass cell cultures [15]. Expression and activation of the majority of cartilage matrix
specific MMPs such as MMP1, MMP7, MMP8, and MMP13, were also decreased by PACAP addition
upon oxidative and mechanical stress, while the activity of MMP9 seemed not to be influenced by
the neuropeptide. They suggest that PACAP is a potent substance that can positively regulate matrix
production in articular cartilage, particularly in the presence of various cellular stress conditions, such
as mechanical overload or oxidative stress, important in the progression of matrix degradation in OA
or rheumatoid arthritis.
3. OA and Physiological Microenvironment
Joint as a whole organ represents tissues with specific cells embedded into a specific environment.
The articular cartilage is avascular and represents an anisotropic tissue with low oxygen tension [16].
Chondrocytes in the different zones of the articular cartilage are adapted to an oxygen gradient
ranging from 5% at the superficial zone to 2% at the calcified zone, which is markedly lower
than that of the normal atmospheric oxygen level (20%). Likewise, the inherent swelling pressure
produced by proteoglycans and the counteracting tensile force exerted by the collagen fibrils result in
higher osmolarity of the cartilage extracellular fluid compared to the osmolarity of the plasma [17].
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Furthermore, the complex interactions of the macromolecular components with tissue fluid determine
the mechanical properties of the cartilage extracellular matrix (ECM) [18]. Hence, normal chondrocytes
exist in a unique physiological microenvironment, and alterations in the environmental factors have a
major contributing role in the pathogenesis of OA.
It has been a long-term hypothesis that application of factors reflecting for the native articular
cartilage environment, such as mechanical stimulation, oxygen tension or osmolarity, during expansion
of mesenchymal stem cells (MSCs) or chondrocytes is vital for the development of cell-based tissue
engineering constructs for cartilage repair. The review by Pattappa et al. provides a comprehensive
insight into the role of hypoxia/physioxia for chondrogenic differentiation of adult MSCs [19]. Exposure
to physioxic conditions (1–5% O2) is beneficial for MSC isolation, expansion and chondrogenic
differentiation compared to normal oxygen tension (20% O2). Particularly, physioxia increases
cartilage-specific gene expression (e.g., collagen II and aggrecan) and matrix synthesis, while
downregulates genes associated with cartilage hypertrophy (e.g., collagen X, collagenases and
aggrecanases). The molecular pathways orchestrating the response of MSCs for physioxia involves
hypoxia-inducible factors (HIFs) and phosphoinositide 3-kinases (PI3Ks). HIFs are heterodimers
consisting of an instable, oxygen-sensitive α subunit and a constitutively expressed, oxygen-insensitive
β subunit. Recent data show that HIF complexes have different roles under physioxia: HIF-1α after
nuclear translocation and dimerization with HIF-1β upregulates chondrogenic gene expression; HIF-2α
enhances the gene expression of cartilage hypertrophic markers and matrix degrading enzymes; while
HIF-3α counters the effect of HIF-2α. In addition, HIF-1α translocation activates the PI3K/Akt/FOXO
pathway, which helps to maintain the chondrogenic phenotype through the reduction of hypertrophic
markers. The review also summarizes the in vivo fate of hypoxia pre-conditioned MSCs after
implantation in animal models.
Jahr and colleagues investigated the mechanistic role of physioxia for maintaining the chondrogenic
phenotype of human articular cartilage chondrocytes in a bioreactor-based microtissue culture
system [20]. The authors showed that 2.5% physioxic oxygen tension is optimal for upregulation of
the chondrogenic marker genes (COL2A1 and ACAN), while suppressing dedifferentiation markers.
Physioxia activated the TGF-β signaling pathway by upregulating all the three TGF-β isoforms,
especially TGF-β2. They found oxygen-dependent regulation of the type I TGF-β receptors activin
receptor like kinases ALK1 and ALK5, and the type III co-receptors betaglycan and endoglin. The 2.5%
O2 preferentially activated the chondrogenic TGF-β-ALK5/Smad2/3 pathway and suppressed the
catabolic TGF-β-ALK1/Smad1/5/8 signaling compared to normoxic conditions. Thus, a balanced ALK5
versus ALK1 receptor-mediated signaling is an important molecular measure in chondrocytes for
adaptation to different oxygen tensions.
Timur et al. attempted to dissect the mechanism underlying the chondrogenic effect of physiological
osmolarity on in vitro cultured human articular cartilage chondrocytes [21]. While normal expansion
culture medium with plasma osmolarity (280 mOsm) induces chondrocyte dedifferentiation, higher
levels of oxygenation mimicking physiological osmolarity of the healthy cartilage (in a range of
380–450 mOsm) favors the elevated expression of the chondrogenic marker gene COL2A1. The
authors partially clarified the molecular mechanism behind COL2A1 induction by demonstrating that
physosmolarity (380 mOsm) induces TGF-β and BMP-2 signaling. TGF-β2 mRNA expression and
protein secretion, TGF-β and BMP bioactivities were all elevated upon physosmotic treatment. Utilizing
the BMP signaling inhibitor dorsomorphin and TGF-β2 knockdown, the authors demonstrated that
TGF-β2 RNAi combined with physosmolarity increases COL2A1 gene expression and TGF-β bioactivity
but does not change BMP activity, while blocking BMP signaling with or without TGF-β2 knockdown
decreases COL2A1 expression irrespective of the medium osmolarity. Interestingly, the authors also
found that independently of the manipulation of TGF-β/BMP signaling, physiological osmolarity
always favors COL2A1 gene expression compared to plasma osmolarity. Thus, the results reveal that
TGF-β superfamily member signaling contributes to physosmolarity-induced COL2A1 expression,
however, the full effect of cartilage-specific physosmotic level on ECM marker synthesis should
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be also modulated by other metabolic, transcriptional or epigenetic factors. Further dissecting the
complex molecular mechanism of physosmosis on articular cartilage chondrocytes, therefore, still is a
prerequisite for improving cell-based repair strategies.
In OA, besides changes in articular cartilage and subchondral bone, the synovium also plays
an important role. Accompanying OA progression, synovial fibroblasts (SF) elicit an immunological
response and produce proinflammatory cytokines. Schröder et al., studied the impact of mechanical
load on the expression profile of SFs derived from normal or OA patients [22]. Static compressive loading
applied on cultured SFs of non-OA donors for 2 days enhanced the expression of proinflammatory
factors such as TNFα, IL-6, and COX-2, reduced the expression of collagen I and fibronectin, and induced
glycosaminoglycan (GAG) production. In contrast, the authors found that SFs from OA-patients are
less responsive for mechanical loading implicating that SFs might have a more prominent role at the
onset of OA than in OA maintenance.
4. OA and Cartilage/Subchondral Bone Extracellular Matrix Turnover
The evolution of OA is associated with functional and structural changes in multiple joint tissues
including the cartilage and the subchondral bone. It is generally accepted that uncontrolled metabolism
of skeletal tissues is critical for the pathophysiology of OA. Physiological ECM remodeling of the
articular cartilage occurs in a spatially and temporally controlled fashion and involves both proteinases
and proteinase inhibitor activities that are tightly regulated at multiple levels. Changes of ECM
composition or alterations of the biomechanical environment of chondrocytes significantly increase
the risk of OA through the perturbation of signaling involved in the maintenance of normal cartilage
differentiation and homeostasis.
The large aggregating protein aggrecan is the most abundant proteoglycan of cartilaginous tissues
and it has been implicated in skeletal disorders including various forms of chondrodysplasias
and OA [23]. Especially during early OA, aggrecan is cleaved by MMPs and aggrecanases,
which in turn makes the collagen fibrils susceptible for degradation as the disease progresses.
Alberton et al., investigated the impact of relative aggrecan levels in the cartilage for skeletal growth
and OA by analyzing the hypomorphic mouse strain Agc1CreERT2 [24]. This mouse line has been
previously established for conditional inactivation of floxed genes in cartilage via the insertion of a
tamoxifen-inducible cre-recombinase-mutant estrogen receptor fusion polypeptide coding cDNA into
the 3´untranslated region (UTR) of the mouse aggrecan gene (Agc1) [25]. The authors demonstrated
that the insertion of the CreERT2 at the UTR causes a hypomorphic mutation by reducing Agc1
mRNA expression in chondrocytes and lowering aggrecan protein deposition in the cartilaginous
tissues. A careful analysis of skeletal development and articular cartilage function in homozygous
animals indicated that the reduced aggrecan level (1) impairs growth of the cartilaginous skeleton
leading to dwarfism and (2) leads to high incidence of spontaneous OA in aged, 1 year old animals.
Mechanistically, aggrecan hypomorphism increased the stiffness of the mutant articular cartilage
when the knee joint was assessed by nano-scale indentation-type atomic force microscopy (IT-AFM).
IT-AFM, applied on native cartilage sections, revealed stiffening of both the proteoglycan moiety and
the collagen fibrils in each zone (superficial, middle, deep) of the articular cartilage. These results
indicate that reduced aggrecan levels in the ECM compromise the biomechanical properties of the
cartilaginous ECM and predispose the articular cartilage for OA-like degeneration. Consequently,
homozygous Agc1CreERT2 mice could not be used for gene ablation experiments in transgenic mice,
however, this mouse strain may be appropriate as a model system to mimic human aggrecanopathies
caused by diminished aggrecan expression in the skeleton.
The thrombospondin (TSP) family of large ECM glycoproteins composed of five members
(TSP1-TSP5), and among them, mutations in TSP-5 (or cartilage oligomeric protein, COMP) cause
human pseudoachondroplasia and multiple epiphyseal dysplasia associated with early onset OA [26].
As the roles of other TSPs for articular cartilage homeostasis are less known, Maly and colleagues
investigated the expression and localization of TSP-4 in healthy and osteoarthritic human knee articular
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cartilage [27]. Immunohistochemistry and immunoblotting revealed that TSP-4 is present at very
low level in normal articular cartilage but its ECM deposition dramatically increases in OA tissues
correlating well with OA severity. Interestingly, TSP-4 expression is not regulated at the transcriptional
level, however, the anchorage of TSP-4 into the cartilage ECM is weaker in early OA. The authors also
demonstrated that intact and degraded forms of TSP-4 are detectable in the serum of healthy controls
and OA patients, with increased abundance of the degradation fragments in patient sera. Thus, this
study suggests that TSP-4 is a potential OA-specific serum biomarker, which besides the widely used
TSP-5/COMP can serve as a novel diagnostic and prognostic tool for knee OA.
Small leucine-rich repeat proteoglycans (SLRPs) constitute a diverse family of small PGs with
expression in articular cartilage and with prominent roles in ECM assembly and homeostasis.
Fibromodulin (FMOD) and lumican (LUM) are class II SLRPs with 12 leucine-rich repeats (LRRs)
and carry keratan sulfate chains [23]. FMOD and LUM have been implicated in modulating collagen
fibrillogenesis and various other biological processes, and they are proteolytically processed for
degradation in OA. Shu et al., performed detailed investigation of FMOD and LUM catabolism
in developing and pathological cartilage tissues using immunohistochemistry and sophisticated
biochemical analyses [28]. The authors found evidences for FMOD and LUM fragmentation in
fibrillated cartilage samples with clear differences in the expression pattern of the full length and the
processed forms. FMOD was found to be highly expressed in the superficial zone of the articular
cartilage, and moderately in the deeper zones, while the FMOD degradation fragment generated by
MMP-13 was highly abundant in each zone of OA cartilage. In cartilage obtained from knee replacement
donors, LUM displayed a predominantly amino-terminal processing, while FMOD degradation was
characterized by fragments processed also at the carboxy-terminus. Furthermore, the authors revealed
that FMOD and LUM are differentially processed by degradative proteases in an in vitro cartilage
digestion model. FMOD was susceptible for degradation by MMP-13, ADAMTS-4, and to a lesser
extent to ADAMTS-5, and produced fragments similar to that ones, which were found in OA cartilage.
In contrast, those enzymes were unable to significantly degrade LUM. The authors also suggest that
the identified FMOD fragments, especially products generated by MMPs, can be useful OA biomarkers
to monitor disease progression between early aggrecanolysis and the later collagenolysis.
The study by Smith and Melrose demonstrated that ovine articular cartilage chondrocytes
synthesise Kunitz serine proteinases inhibitors (SPIs), which belongs to the inter-α-trypsin inhibitor
(ITT) superfamily [29]. Kunitz SPIs are multifunctional proteins and the authors proposed that they may
protect hyaluronan and the articular cartilage surface protein lubricin from proteolytic degradation,
hence, preserve the joint function.
It is becoming increasingly evident that alterations of the subchondral bone contribute to the
pathophysiology of OA, which often precede the degradation of the articular cartilage during aging [30].
The calcified cartilage (CC) and the underlying subchondral bone plate (SCBP) define the mineralized
subchondral bony zone (SCZ) of the joint, which undergoes age- and disease-dependent structural
and material changes. Taheri et al., studied maturation-associated alterations of healthy SCZ in
calves (3 months of age) and cattle (12 months of age) [31]. The authors showed that the entire
SCZ was significantly thicker in cattle compared to calves, however, the ratios of the CC and SCBP
were relatively constant in the two age groups. They found that the number of trabeculae and their
connectivity significantly increased as the region shifted from CC to the SCBP, while the bone volume
fraction and the degree of anisotropy were primarily influenced by the age and not by the SCZ region.
High-resolution micro-CT (micro-computed tomography) imaging showed that superior surface of
the subchondral bone was connected to deeper trabecular bone via microchannel structures. These
microchannels were abundant and narrow in calves, while thicker and less frequent in cattle, probably
due to adaptation to age-dependent requirements of nutrition and oxygenation. Moreover, older
animals exhibited higher mineralization throughout the SCZ, while mineralization increased within
the first 250 µm of SCZ independently of the age. The results imply that SCZ is highly dynamic in
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structure and composition during the maturation phases, which may help to understand and identify
factors leading to early OA.
5. OA and Transcriptome
In OA, chondrocytes undergo marked transcriptional changes that compromise their function
leading to cartilage degradation. Gene expression profiling of normal and OA articular chondrocytes
is pivotal to understand molecular mechanisms, which either induce OA or protect articular cartilage
against degeneration. The identification of transcription and epigenetic factors involved in the control
of gene expression and the pathogenesis of OA has also a crucial importance [32]. These studies could
contribute to determining potential OA biomarkers and to developing novel therapies for osteoarthritis.
Forkhead box O (FoxO) transcription factors regulate diverse cellular processes including oxidative
stress response, metabolism, and autophagy in chondrocytes. The expression of FoxOs is reduced
with aging and in OA suggesting an important role of FoxOs in joint homeostasis. The review by
Wang et al., integrates our recent understanding of FoxOs on oxidative stress-induced chondrocyte
dysfunction and highlight their potential as targets for OA treatment [33]. Increased ROS production
and oxidative stress upregulate the expression of FoxOs, which in turn enhances the expression of
antioxidant enzymes. In contrast, downregulation of FoxO in chondrocytes leads to intracellular
oxidative stress and apoptosis.
Joint injury is an important risk factor for post-traumatic osteoarthritis (PTOA), which constitutes
at least 12% of all knee OA. Injury-induced PTOA is not well understood, therefore non-invasive
injury models in mice are crucial to gain insight into the pathomechanism of PTOA. Sebastian et al.,
induced PTOA by rupturing the anterior cruciate ligament (ACL) by using a tibial compression joint
injury model in mouse strains with various susceptibility to OA [34]. Performing RNA sequencing on
whole joint samples before and after the injury at various time point in highly OA susceptible STR/ort
mice, in moderately susceptible C57BL/6J mice and non-susceptible, super-healer MRL/Mpj mice, the
authors identified a massive amount of genes, which were differentially regulated in these strains.
Gene expression analysis has revealed that persistent inflammation, elevated catabolic activity and
apoptosis are the most significant contributors for the severe PTOA development in STR/ort mice.
Comparing the gene expression profiles of the super-healer and OA susceptible mice, several genes
including B4galnt2 (beta-1,4 N-acetylgalactosaminyltransferase 2) and Tpsab1 (tryptase alpha/beta 1)
were identified, which are potentially involved in enhanced healing. Additional genes as biomarkers
for ACL-induced PTOA were also described, including Mamdc2 (MAM domain containing 2), which is
expressed at very low level in MRL/Mpj mice but was moderately expressed in the other two strains.
Thus, this study provides novel candidate genes and molecular pathways, which are associated with
PTOA development and tissue regeneration.
Obesity among the most important risk factors of OA and adipose tissue-produced adipokines
have been implicated in cartilage metabolism and OA pathogenesis. In the last decade, numerous
microRNAs (miRNAs) have been identified as regulators of chondrocyte signaling pathways and OA
initiation and progression. Cheleschi and colleagues investigated the interaction between adipokines
and miRNAs known to be involved in OA [35]. The adipokines visfatin and resistin increased apoptosis,
MMP-1 and MMP-13 gene expression, while reduced COL2A1 expression in human OA chondrocytes.
These adipokines exerted their effects partially through the NF-kB signaling pathway, since an NF-kB
inhibitor ameliorated the adipokine-induced catabolic changes. Visfatin and resistin modulated the
expression of several miRNAs by upregulating the apoptosis-inducing miR-34a, and the catabolic
miR-155, miR-181a, and miR-let7e, and by downregulating the anti-catabolic miR-140 and miR-146a.
These data strengthen the connection between adipokines and miRNAs in OA pathogenesis.
Identification of genetic components for rheumatoid arthritis and OA in the human population
has an obvious importance. Huber et al., have identified single nucleotide polymorphisms (SNPs) in
the promoters of the proto-oncogens JUN and FOS in patients with rheumatoid diseases [36]. JUN
and FOS form heterodimers resulting in the AP-1 (activator protein-1) transcription factor which has
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been implicated in rheumatic diseases. The authors functionally validated the identified SNPs by
reporter assays and found that one JUN SNP downregulates, whereas two FOS SNPs upregulate the
corresponding promoter activity. The association of the functionally relevant FOS SNPs with knee-OA
was demonstrated in German and Finish study cohorts.
6. OA and Diabetes Mellitus
Diabetes Mellitus (DM), i.e., Type 2, and knee OA often coexist and share various risk factors
such as obesity and aging. While the mechanical impact of excess body weight on joints may explain
lower limb OA, it is unclear whether type 2 diabetes mellitus (T2DM) is linked to OA outside of excess
weight and whether T2DM may play a role in OA pathophysiology. An association between the
occurrence of T2DM and OA has been demonstrated, although a causal link is not well established [37].
T2DM has a pathogenic effect on OA through two major pathways: (1) Chronic hyperglycemia, which
induces oxidative stress, overproduction of pro-inflammatory cytokines and advanced glycanation
end products (AGEs) in joint tissues; and (2) insulin resistance, which could play a role locally but also
through the systemic low-grade inflammatory state [38].
Silawal et al., investigated about the role of the anti-inflammatory and chondroprotective cytokine
interleukin (IL)-10 in the interrelation between OA and DM [39]. The authors cultured human articular
OA chondrocytes (hAC) and a chondrosarcoma cell line (OUMS-27) under normoglycemic (NG) and
hyperglycemic (HG) conditions and stimulated them with insulin and/or IL-10. The chondrosarcoma
cell line OUMS-27 was tested to reveal if it represents a reliable and reproducible chondrocyte
T2DM model system. Cell survival, metabolic activity, proliferation, and ECM synthesis were
immunocytochemically examined. In the present model, the metabolism of hAC was impaired by
HG conditions alone as well as by HG conditions combined with hyperinsulinemia (HI), IL-10 or the
combination of HI+IL-10. The treatment of cultured hAC with IL-10 led to a significant decrease in
the non-specific and dedifferentiation associated collagen type I (only at NG), cartilage proteoglycans
(under both, NG and HG conditions) as well as the chondrogenic master transcription factor SOX9
(only under HG condition) compared to NG. Hence, the data show that inducing a continuous latent
inflammation by HG might interfere with some anabolic IL-10 actions and explain the impaired
expression of chondrogenic markers observed under HG conditions. Notably, IL-10 treatment of
OUMS-27 did not show any significant effect, suggesting their limited responsiveness in comparison
to primary chondrocytes and are not recommended as T2DM model for OA research.
Dubey et al., conducted dry-to-wet lab research approaches to assess the correlation of type
1 diabetes mellitus (T1DM) and type 2 DM (T2DM) with knee OA among all age and genders of
Taiwanese population discriminating further between obese and non-obese patients [40]. The study
population included 37,353 T1DM and 1,218,254 T2DM patients and it was adjusted according to
age and gender. The authors observed a significant association of knee OA with T1DM and T2DM
pathology. The association between T1DM and knee OA among the obese was insignificant compared
to the non-obese. Interestingly, a higher association between T2DM and knee OA among non-obese
persons compared to the obese was noted. In order to verify the data, the authors used a streptozotocin
(STZ)-derived, diabetes-induced model in non-obese male C57BL/6J mice where they analyzed knee
cartilage degradation after 4 weeks of STZ administration. They demonstrated a higher accumulation
of carboxymethyl lysine (AGE) in the knee joints of diabetic mice, a higher expression of MMP-1 and
a reduced expression of chondrocyte-specific proteins, including SOX9, Collagen II, and aggrecan.
The observation that resulted in a higher strength of association (OR) between DM and knee OA was
confirmed in non-obese diabetic mice (high blood-glucose level) revealing degraded articular cartilage
and depleted proteoglycans. These data indicate that DM is strongly associated with knee OA, whereas
obesity may not be a confounding factor.
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7. Summary
OA can be initiated by multiple factors at multiple sites and its exact etiology is still unclear. Current
pharmacological strategies either seek to relieve pain and increase mobility (symptom modifying drugs)
or aim to affect the disease (DMOAD, disease modifying osteoarthritis drugs). To date, none of the
current DMOAD-based approaches will stop disease progression, nor regenerate damaged cartilage.
In order to develop regenerative treatment strategies, it is required to gain detailed knowledge of
molecular mechanisms accompanying and triggering OA and in particular, to obtain tools to diagnose
beginning OA as early as possible.
We would like to thank all the authors for their contributions. The goal of the issue is to stimulate
research, dissemination of knowledge and discussion in the growing field of OA research.
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